CN104684580A - 抗体制剂及其用途 - Google Patents

抗体制剂及其用途 Download PDF

Info

Publication number
CN104684580A
CN104684580A CN201380046405.2A CN201380046405A CN104684580A CN 104684580 A CN104684580 A CN 104684580A CN 201380046405 A CN201380046405 A CN 201380046405A CN 104684580 A CN104684580 A CN 104684580A
Authority
CN
China
Prior art keywords
formulation
antibody
amino acid
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380046405.2A
Other languages
English (en)
Chinese (zh)
Inventor
S.贝内迪特
M.C.曼宁
B.M.墨菲
S.里尔
C.朔伊尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tracon Pharmaceuticals Inc
Original Assignee
Tracon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tracon Pharmaceuticals Inc filed Critical Tracon Pharmaceuticals Inc
Priority to CN201810659773.9A priority Critical patent/CN108785669A/zh
Publication of CN104684580A publication Critical patent/CN104684580A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201380046405.2A 2012-09-05 2013-09-05 抗体制剂及其用途 Pending CN104684580A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810659773.9A CN108785669A (zh) 2012-09-05 2013-09-05 抗体制剂及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261697111P 2012-09-05 2012-09-05
US61/697111 2012-09-05
PCT/US2013/058265 WO2014039682A1 (en) 2012-09-05 2013-09-05 Antibody formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810659773.9A Division CN108785669A (zh) 2012-09-05 2013-09-05 抗体制剂及其用途

Publications (1)

Publication Number Publication Date
CN104684580A true CN104684580A (zh) 2015-06-03

Family

ID=50237600

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380046405.2A Pending CN104684580A (zh) 2012-09-05 2013-09-05 抗体制剂及其用途
CN201810659773.9A Pending CN108785669A (zh) 2012-09-05 2013-09-05 抗体制剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810659773.9A Pending CN108785669A (zh) 2012-09-05 2013-09-05 抗体制剂及其用途

Country Status (19)

Country Link
US (2) US10195281B2 (enExample)
EP (1) EP2892559A4 (enExample)
JP (3) JP2015532657A (enExample)
KR (2) KR20180007014A (enExample)
CN (2) CN104684580A (enExample)
AU (2) AU2013312536B2 (enExample)
BR (1) BR112015004875A2 (enExample)
CA (1) CA2883343A1 (enExample)
EA (1) EA029214B1 (enExample)
GE (1) GEP201706789B (enExample)
HK (1) HK1210714A1 (enExample)
IL (1) IL237287A0 (enExample)
MX (1) MX368996B (enExample)
MY (1) MY180157A (enExample)
NZ (1) NZ705109A (enExample)
PH (1) PH12015500480B1 (enExample)
SG (2) SG10201705070PA (enExample)
UA (1) UA115789C2 (enExample)
WO (1) WO2014039682A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478820A (zh) * 2016-10-10 2017-03-08 米度（南京）生物技术有限公司 一种肝癌pet诊断示踪剂及其制备方法与用途
CN106928359A (zh) * 2015-12-30 2017-07-07 广西医科大学 一种CD105纳米抗体Nb59
CN106928355A (zh) * 2015-12-30 2017-07-07 广西医科大学 一种CD105纳米抗体Nb184

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2019099921A2 (en) * 2017-11-17 2019-05-23 Amgen Inc. Vegfr-fc fusion protein formulations
BR112020015052A2 (pt) * 2018-02-09 2020-12-08 Genmab A/S Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
CN112717129A (zh) * 2019-10-14 2021-04-30 百奥泰生物制药股份有限公司 抗vegf抗体制剂
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
EP4168038A1 (en) 2020-06-18 2023-04-26 Regeneron Pharmaceuticals, Inc. Activin a antibody formulations and methods of use thereof
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
IL322368A (en) 2023-02-03 2025-09-01 Genzyme Corp HSC-specific antibody-conjugated lipid nanoparticles and their uses
WO2025217334A1 (en) * 2024-04-09 2025-10-16 Regeneron Pharmaceuticals, Inc. Low concentration vegf receptor fusion protein containing formulations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084015A (zh) * 2004-10-20 2007-12-05 健泰科生物技术公司 组氨酸－醋酸盐缓冲液中的抗体制剂
WO2010032059A2 (en) * 2008-09-19 2010-03-25 Medimmune Llc Targeted binding agents directed to cd105 and uses thereof
WO2010039873A2 (en) * 2008-10-01 2010-04-08 Tracon Pharmaceuticals, Inc. Humanized endoglin antibodies
WO2011022339A1 (en) * 2009-08-17 2011-02-24 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
WO2011041441A1 (en) * 2009-09-30 2011-04-07 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2012003470A2 (en) * 2010-07-02 2012-01-05 Medimmune, Llc Antibody formulations

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US928641A (en) 1908-10-09 1909-07-20 Levi E Edmunds Clasp for pilings.
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5308626A (en) 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20020136725A1 (en) 1996-01-17 2002-09-26 Smithkline Beecham Corporation Antithrombotic agents
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP0938505B1 (en) 1996-05-31 2002-03-06 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy
US6190660B1 (en) 1996-05-31 2001-02-20 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy
US5796097A (en) 1997-03-05 1998-08-18 California Lightwave Laboratories, Inc. Chemical sensor and method
ATE230277T1 (de) * 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DE10013850A1 (de) * 2000-03-15 2001-09-20 Schering Ag Gasgefüllte Mikrokapseln enthaltend funktionalisiertes Polyalkylcyanacrylat, sowie Verfahren zu deren Herstellung
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
JP4279554B2 (ja) 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
WO2002072824A2 (en) 2001-02-20 2002-09-19 Bayer Aktiengesellschaft Human transient receptor potential channel protein.
CA2444483A1 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
US20030129193A1 (en) 2001-09-27 2003-07-10 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coaguligand treatment
US7115716B2 (en) 2001-11-19 2006-10-03 Eli Lilly And Company Tumor specific monoclonal antibodies
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7754884B2 (en) 2005-01-03 2010-07-13 Vanderbilt University Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging
US7097836B1 (en) 2002-10-23 2006-08-29 Health Research, Inc. Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
US7691374B2 (en) 2002-10-23 2010-04-06 Health Research, Inc. Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US7120987B2 (en) 2003-08-05 2006-10-17 Avery Dennison Corporation Method of making RFID device
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
BRPI0608468A2 (pt) 2005-03-25 2010-01-05 Glycart Biotechnology Ag moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
AU2006291005A1 (en) 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
US20070077310A1 (en) 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
WO2008039761A2 (en) * 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
AU2007301599B2 (en) 2006-09-28 2013-01-10 Merck Serono S.A. Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
CA2665567C (en) 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
EP2125016A2 (en) 2007-02-01 2009-12-02 Genetech, Inc. Combination therapy with angiogenesis inhibitors
CN101970472B (zh) 2007-06-06 2013-10-30 研究发展基金会 Rtef-1变体及其用于抑制血管发生的用途
WO2009026122A1 (en) * 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
CA2699349C (en) 2007-09-14 2016-04-19 Bayer Schering Pharma Aktiengesellschaft Substituted tricyclic heterocyclic compounds for use as egfr inhibitors
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
CN101970670B (zh) 2008-01-14 2013-08-21 健泰科生物技术公司 使用egfl8拮抗剂抑制血管发生的方法
RS52164B (sr) 2008-08-29 2012-08-31 Bayer Pharma Aktiengesellschaft N-(2-aminofenil)-4-[n-(piridin-3-il)-metoksikarbonilaminometil]-benzamid (ms-275)polimorf b
US8699361B2 (en) 2008-09-30 2014-04-15 Qualcomm Incorporated Out-of-synchronization handling method and apparatus
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
US20180057602A1 (en) 2009-08-17 2018-03-01 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
EP3549952A1 (en) 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
WO2013019805A1 (en) 2011-08-01 2013-02-07 Tufts Medical Center, Inc. Treatment of heart failure and related conditions
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
WO2015042269A1 (en) 2013-09-20 2015-03-26 Tufts Medical Center, Inc. Methods and compositions for reducing cardiac damage and other conditions
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084015A (zh) * 2004-10-20 2007-12-05 健泰科生物技术公司 组氨酸－醋酸盐缓冲液中的抗体制剂
WO2010032059A2 (en) * 2008-09-19 2010-03-25 Medimmune Llc Targeted binding agents directed to cd105 and uses thereof
WO2010039873A2 (en) * 2008-10-01 2010-04-08 Tracon Pharmaceuticals, Inc. Humanized endoglin antibodies
WO2011022339A1 (en) * 2009-08-17 2011-02-24 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
WO2011041441A1 (en) * 2009-09-30 2011-04-07 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2012003470A2 (en) * 2010-07-02 2012-01-05 Medimmune, Llc Antibody formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D. LOWE,ET AL: "Aggregation, stability, and formulation of human antibody therapeutics", 《ADV PROTEIN CHEM STRUCT BIOL》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106928359A (zh) * 2015-12-30 2017-07-07 广西医科大学 一种CD105纳米抗体Nb59
CN106928355A (zh) * 2015-12-30 2017-07-07 广西医科大学 一种CD105纳米抗体Nb184
CN106928359B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种CD105纳米抗体Nb59
CN106478820A (zh) * 2016-10-10 2017-03-08 米度（南京）生物技术有限公司 一种肝癌pet诊断示踪剂及其制备方法与用途

Also Published As

Publication number Publication date
HK1210714A1 (en) 2016-05-06
PH12015500480A1 (en) 2015-04-27
KR101820582B1 (ko) 2018-01-22
EP2892559A1 (en) 2015-07-15
US20180311359A1 (en) 2018-11-01
JP6445671B2 (ja) 2018-12-26
SG10201705070PA (en) 2017-07-28
MX2015002840A (es) 2015-08-12
WO2014039682A1 (en) 2014-03-13
IL237287A0 (en) 2015-04-30
JP2015532657A (ja) 2015-11-12
CA2883343A1 (en) 2014-03-13
MX368996B (es) 2019-10-23
AU2013312536A1 (en) 2015-03-05
JP6602446B2 (ja) 2019-11-06
US20150209430A1 (en) 2015-07-30
EA201590412A1 (ru) 2015-08-31
NZ705109A (en) 2018-04-27
JP2019059753A (ja) 2019-04-18
BR112015004875A2 (pt) 2017-11-21
UA115789C2 (uk) 2017-12-26
US10195281B2 (en) 2019-02-05
MY180157A (en) 2020-11-23
EP2892559A4 (en) 2016-05-11
KR20150048877A (ko) 2015-05-07
EA029214B1 (ru) 2018-02-28
JP2018076350A (ja) 2018-05-17
CN108785669A (zh) 2018-11-13
SG11201501659SA (en) 2015-04-29
AU2013312536B2 (en) 2018-04-19
AU2018204044A1 (en) 2018-06-28
GEP201706789B (en) 2017-12-11
PH12015500480B1 (en) 2015-04-27
KR20180007014A (ko) 2018-01-19

Similar Documents

Publication Publication Date Title
JP6602446B2 (ja) 抗体製剤及びその使用
CN102711809B (zh) 使用抗-内皮因子抗体和抗-vegf剂联合治疗癌症
KR101398707B1 (ko) 엔도글린 항체
US20180057602A1 (en) Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150603